- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00099177
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
August 14, 2017 updated by: Hoffmann-La Roche
A Randomized, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain
This 2 arm study will compare the efficacy of a regimen of intravenous (iv) and oral Bondronat with that of zoledronic acid in patients with malignant bone disease experiencing moderate to severe pain.
Patients will be randomized to receive either Bondronat (6mg iv on days 1, 2 and 3 followed by Bondronat 5Omg po daily from day 22 to week 24) or zoledronic acid (4mg iv on day 1, and then every 3-4 weeks).
The anticipated time of study treatment is 6-12 months, and the target sample size is 100-500 individuals.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
96
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bahia Blanca, Argentina, B8001HXM
-
Buenos Aires, Argentina, 1426
-
Buenos Aires, Argentina, C1426BOR
-
Rosario, Argentina, 2000
-
Santa Fe, Argentina, 03000
-
-
-
-
-
Adelaide, Australia, 5011
-
Brisbane, Australia, 4101
-
-
-
-
-
Santiago, Chile
-
Vina Del Mar, Chile
-
-
-
-
-
Hamburg, Germany, 22143
-
-
-
-
-
Kalyftaki Kifissia, Greece
-
Thessaloniki, Greece, 57010
-
-
-
-
-
Guatemala City, Guatemala
-
-
-
-
-
Budapest, Hungary, 1122
-
Budapest, Hungary, 1529
-
Deszk, Hungary, 6772
-
Szeged, Hungary, 6720
-
-
-
-
-
Rozzano, Italy, 20089
-
Torino, Italy, 10126
-
-
-
-
-
La Paz, Mexico, 23040
-
Mexicali, Mexico, 21100
-
Mexico City, Mexico, 14050
-
Monterrey, Mexico, 64320
-
-
-
-
-
Panama City, Panama, 83-0669
-
-
-
-
-
Poznan, Poland, 60-569
-
Poznan, Poland, 61-878
-
-
-
-
-
San Juan, Puerto Rico, 00935
-
-
-
-
-
Kazan, Russian Federation, 420029
-
Moscow, Russian Federation
-
Moscow, Russian Federation, 125284
-
Moscow, Russian Federation, 115478
-
Moscow, Russian Federation, 117837
-
Obninsk, Russian Federation, 249020
-
St Petersburg, Russian Federation, 197022
-
St Petersburg, Russian Federation, 197758
-
-
-
-
-
St Gallen, Switzerland, 9007
-
-
-
-
-
Manchester, United Kingdom, M20 4BX
-
Sutton, United Kingdom, SM2 5PT
-
-
-
-
Florida
-
Miami, Florida, United States, 33136
-
-
Georgia
-
Macon, Georgia, United States, 31201
-
-
Texas
-
Houston, Texas, United States, 77030
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with malignant bone disease;
- patients with moderate to severe pain.
Exclusion Criteria:
- patients who have received a bisphosphonate within 3 weeks from the signing of informed consent;
- patients receiving concurrent investigational therapy, or who have received investigational therapy within 30 days of the first scheduled day of dosing;
- untreated esophagitis or gastric ulcers;
- recent or pre-scheduled radiotherapy to bone;
- patients who are pregnant or breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
6mg iv on days 1-3, and 50mg po from day 22 to week 24
|
Active Comparator: 2
|
4mg iv on day 1, and every 3-4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pain, as measured by Brief Pain Inventory and analgesic use
Time Frame: Week 24
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AEs and laboratory parameters
Time Frame: Throughout study
|
Throughout study
|
Performance score and QoL measures
Time Frame: Week 24
|
Week 24
|
Opioid side effects
Time Frame: Throughout study
|
Throughout study
|
Skeletal-related events
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2005
Primary Completion (Actual)
December 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
December 10, 2004
First Submitted That Met QC Criteria
December 9, 2004
First Posted (Estimate)
December 10, 2004
Study Record Updates
Last Update Posted (Actual)
August 16, 2017
Last Update Submitted That Met QC Criteria
August 14, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BO18039
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pain
-
Flowonix MedicalApproved for marketingBack Pain | Leg Pain | Trunk Pain | Intractable Pain | Arm Pain
-
University Hospital Schleswig-HolsteinZealand University Hospital; European Regional Development Fund; Design School...CompletedPain, Acute | Pain, Chronic | Pain Measurement | Pain, CancerGermany
-
Universitat Jaume ICompletedPain, Acute | Pain, Chronic | OncologySpain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Dr. Negrin University HospitalCompletedPostoperative Pain, Acute | Postoperative Pain, ChronicSpain
-
George Washington UniversityRecruitingCervical Fusion | Pain, Back | Pain, Neck | Myofacial PainUnited States
-
University of Campinas, BrazilCompletedPREGNANCY | LUMBAR BACK PAIN | PELVIC PAIN
-
Atatürk Chest Diseases and Chest Surgery Training...RecruitingPostoperative Pain | Postoperative Pain, Acute | Postoperative Pain, Chronic | VATSTurkey
-
Janssen Research & Development, LLCCompletedPain, Radiating | Pain, Burning | Pain, Crushing | Pain, Migratory | Pain, SplittingUnited States, France, Spain, Poland, Portugal
-
susanne beckerSNSFCompletedLow Back Pain | Pain, Acute | Pain, ChronicSwitzerland
Clinical Trials on ibandronate [Bondronat]
-
Hoffmann-La RocheCompletedPain; Bone Neoplasms; Neoplasm MetastasisBulgaria
-
Hoffmann-La RocheWithdrawnPain | Neoplasm Metastasis | Bone NeoplasmGreece
-
Hoffmann-La RocheCompletedPain; Bone Neoplasms; Neoplasm MetastasisBulgaria
-
Hoffmann-La RocheCompletedPain; Bone Neoplasms; Neoplasm MetastasisTurkey
-
Hoffmann-La RocheCompletedPain; Bone Neoplasms; Neoplasm MetastasisFrance
-
Chinese Society of Lung CancerTerminated
-
Hoffmann-La RocheCompletedPain; Bone Neoplasms; Neoplasm MetastasisHungary
-
Hoffmann-La RocheTerminatedPain | Neoplasm Metastasis | Bone NeoplasmUnited States, Mexico, Germany, Russian Federation, Italy, Hungary, Belgium, Chile, France, Argentina, Australia, Switzerland, Guatemala, Puerto Rico, Poland, Panama, United Kingdom, Canada
-
Hoffmann-La RocheRoche Pharma AGTerminatedMultiple MyelomaGermany